REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$12.41 USD
-0.67 (-5.12%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $12.40 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for REGENXBIO Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -263.49 | -280.32 | 127.84 | -111.25 | -94.73 |
Depreciation/Amortization & Depletion | 18.01 | 17.62 | 15.41 | 9.49 | 5.96 |
Net Change from Assets/Liabilities | -10.89 | 13.98 | 40.22 | 14.22 | -5.32 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 37.97 | 41.24 | 35.41 | 33.48 | -13.60 |
Net Cash From Operating Activities | -218.41 | -207.49 | 218.88 | -54.06 | -107.71 |
Property & Equipment | -9.96 | -30.72 | -84.18 | -26.87 | -11.72 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 200.90 | 18.80 | -322.47 | 149.63 | 105.28 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 190.94 | -11.93 | -406.64 | 122.76 | 93.56 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.22 | 4.55 | 222.49 | 7.42 | 8.38 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -43.19 | -33.39 | -27.24 | 192.79 | 0.00 |
Net Cash from Financing Activities | -34.97 | -28.84 | 195.25 | 200.21 | 8.38 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -62.43 | -248.26 | 7.48 | 268.91 | -5.77 |
Cash at Beginning of Period | 98.98 | 347.24 | 339.76 | 70.84 | 76.61 |
Cash at End of Period | 36.55 | 98.98 | 347.24 | 339.76 | 70.84 |
Diluted Net EPS | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 |
Fiscal Year End for REGENXBIO Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -63.33 | -263.49 | -200.61 | -138.74 | -66.68 |
Depreciation/Amortization & Depletion | 3.71 | 18.01 | 13.91 | 9.68 | 4.86 |
Net Change from Assets/Liabilities | -8.16 | -10.89 | -20.11 | -19.49 | -29.61 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 12.32 | 37.97 | 29.15 | 20.31 | 10.51 |
Net Cash From Operating Activities | -55.46 | -218.41 | -177.65 | -128.24 | -80.92 |
Property & Equipment | -0.56 | -9.96 | -8.83 | -7.40 | -4.82 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.74 | 200.90 | 165.80 | 125.71 | 67.91 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 13.18 | 190.94 | 156.97 | 118.31 | 63.09 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 132.90 | 8.22 | 8.01 | 1.80 | 1.05 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -12.17 | -43.19 | -31.02 | -20.00 | -10.09 |
Net Cash from Financing Activities | 120.73 | -34.97 | -23.00 | -18.20 | -9.04 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 78.45 | -62.43 | -43.68 | -28.13 | -26.86 |
Cash at Beginning of Period | 36.55 | 98.98 | 98.98 | 98.98 | 98.98 |
Cash at End of Period | 115.01 | 36.55 | 55.30 | 70.86 | 72.12 |
Diluted Net EPS | -1.38 | -1.42 | -1.41 | -1.66 | -1.53 |